From: Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
N (%) or Median (IQR) | |
---|---|
Sensorineural Hearing Loss | 6 (12.2%) |
Bilateral | 4/6 (66.7%) |
High frequency (> 2000 Hz) | 5/6 (83.3%) |
Very high frequency (> 10,000 Hz) | 1/6 (16.7%) |
Severe hearing loss | 0/6 (0%) |
Subjective hearing loss | 10 (22%) |
Subjective tinnitus | 15 (31.9%) |
Subjective dizziness | 4 (8.5%) |
Nephrotoxicity | |
Baseline serum creatinine | 64 (51, 73) |
Peak serum creatinine | 90 (76, 106) |
End of treatment serum creatinine | 76 (64, 92) |
Number of patients with nephrotoxicity | 10/43 (23.3%) |
% recovery by end of treatment | 2/10 (20%) |
GFR < 60 at end of treatment | 5 (11.9%) |
Proportion of patients who discontinued amikacin prematurely due to AE | 21% (17–43%) |